Clinical trials: Induction Chemotherapy
Biliary Cancer
Pembrolizumab and GM-CSF in Biliary Cancer
This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at University of California, San Francisco…
- Trial name
- NCT02703714
- Testing
- Pembrolizumab, Sargramostim
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Robin Kate Kelley
Breast Cancer, Chemotherapy-Related Cognitive Impairment
Behavior Change Wheel-Based Music Listening for Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients
Breast cancer patients frequently experience chemotherapy-related cognitive impairment (CRCI), which can negatively affect memory, attention, executive function, daily activities, and quality of life.
- Trial name
- BCW-MUSIC (NCT07641114)
- Testing
- BCW-Based Music Listening Intervention, Routine Nursing Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Chemotherapy-induced Nausea and Vomiting
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
In this study, patients will receive ondansetron 8mg and dexamethasone 10mg intravenously 30 minutes prior to myeloablative preparative chemotherapy until the last day of chemotherapy.
- Trial name
- NCT01370408
- Testing
- Palonosetron, ondansetron, Dexamethasone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Northside Hospital, Inc.
Chemotherapy-induced Peripheral Neuropathy
Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy
This protocol describes a phase II trial investigating the efficacy of CBD in paclitaxel- and oxaliplatin-induced peripheral neuropathy.
- Trial name
- CINCAN-2 (NCT04582591)
- Testing
- Cannabidiol 100 MG/ML
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- Zealand University Hospital
Non-small Cell Lung Cancer
Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer
TLK199.2102 was a multicenter Phase 2 randomized study to determine the effect of Telintra treatment on chemotherapy induced neutropenia (CIN) in patients with non small cell lung cancer receiving first-line therapy with…
- Trial name
- NCT00701870
- Testing
- ezatiostat hydrochloride (Telintra®)
- Where
- 24 sites in United States
- Volunteers
- 1 people
- Sponsor
- Telik
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
This phase II trial investigates how well duloxetine and neurofeedback training work in treating patients with chemotherapy induced peripheral neuropathy.
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04560673
- Testing
- Duloxetine, Neurofeedback, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 336 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT assessment to change the following chemoradiotherapy regiment for locally…
- Trial name
- NCT06420908
- Testing
- Adebrelimab+TP/FP+ radiation therapy, Adebrelimab+FP/TP+ radiation therapy
- Sponsor
- Hebei Medical University Fourth Hospital
Efficacy, Safety
Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients
- Conditions
- Efficacy, Safety, Megestrol Acetate, Adult Subject
- Trial name
- NCT07130617
- Testing
- Low dose of Megestrol Acetate Oral Suspension combined with standard therapy, Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy, High dose of Megestrol Acetate Oral Suspension combined with standard therapy
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Breast Cancer
Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting toxicity of taxane-based agents, with an incidence of 57%-83%.
- Trial name
- NCT07344974
- Testing
- Traditional Chinese medicine (TCM) hand and foot baths, Methylcobalamin (methylB12)
- Volunteers
- 78 people
- Sponsor
- Peking University Cancer Hospital & Institute
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.
- Trial name
- EASE (NCT00619359)
- Testing
- Comparator: fosaprepitant dimeglumine, Comparator: Aprepitant, Dexamethasone
- Volunteers
- 2,322 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphopenia
Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy
This is a protocol for expanded access use of nogapendekin-alfa inbakicept (NAI) in participants with lymphopenia induced by chemotherapy, immunotherapy, and/or radiation therapy who may benefit from its use, and who are…
- Trial name
- NCT06956547
- Testing
- nogapendekin-alfa inbakicept
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Cannabis Use Disorder
Lemborexant for Cannabis Use Disorder
The goal of this clinical trial is to investigate the use of Lemborexant as a treatment for moderate to severe Cannabis Use Disorder (CUD). The main questions it aims to answer are: 1.
- Trial name
- LemboCAN (NCT07802990)
- Testing
- Lemborexant 10mg, Brief Behavioural Intervention
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University of Calgary
Mucositis, Chemotherapeutic Toxicity
The Efficacy and Safety of a Compound Glutamine Capsule in the Primary Prevention of Chemotherapy-induced Mucositis
Chemotherapy regimens not only improve the survival of patients with gastric cancer and colorectal cancer, but also cause obvious adverse reactions of digestive tract, such as chemotherapy-induced oral mucositis, abdominal pain…
- Trial name
- NCT05092113
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Meng Qiu
Chemotherapy-induced Nausea and Vomiting
Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.
- Trial name
- NCT05319860
- Testing
- Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV), Aromatherapy Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Lymphoma
PET-based Evaluation of Chemotherapy-induced Brain Damage in Lymphoma
Positron emission tomography (PET) with 18-fluoro-deoxy-glucose (PET-FDG) is emerging as a promising approach for detecting brain lesions in dementia, among which Alzheimer's disease has been the most widely studied.
- Trial name
- LYMCOTEP (NCT02601547)
- Testing
- PET-FDG brain imaging and NPT
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Toulouse
Neuropathy
Pilates Versus Gyrotonic Expansion System on Chemotherapy Induced Peripheral Neuropathy and Fall Risk
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting side effect of neurotoxic chemotherapy (ie, taxanes, vinca alkaloids, platinum, and bortezomib) that interferes with patients' daily function and…
- Trial name
- NCT07137078
- Testing
- pilates, gyrotonic expansion exercise
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- MTI University
Non-small Cell Lung Cancer, Esophageal Cancer
Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic…
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
- Trial name
- CorTox (NCT06986291)
- Testing
- Imaging and biomarkers
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- Technische Universität Dresden
Breast Cancer
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab.
- Trial name
- PROTECT (NCT06341842)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Chemotherapy-induced Peripheral Neuropathy
NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who…
- Trial name
- NCT04112641
- Testing
- Nicotinamide riboside
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Donna Hammond, PhD
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)
Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of tipifarnib in treating patients who have acute myeloid leukemia or myelodysplastic…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00045396
- Testing
- tipifarnib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.